首页> 外文期刊>Aviation, space, and environmental medicine. >USAF treatment table 8: treatment for altitude decompression sickness.
【24h】

USAF treatment table 8: treatment for altitude decompression sickness.

机译:美国空军的治疗表8:高原减压病的治疗。

获取原文
获取原文并翻译 | 示例
           

摘要

INTRODUCTION: Altitude decompression sickness (DCS) has been treated with hyperbaric therapy since 1941. Treatment has essentially followed the diving DCS paradigm. Expanding space operations and higher flying, more remotely placed military aircraft have stimulated a re-examination of this paradigm. Can the oxygen and pressure-producing resources in these austere environs be reduced without sacrificing treatment efficacy? METHOD: A prospective series of 12 patients was treated with a new treatment table. USAF Treatment Table 8 (TT8) consists of 100% oxygen delivered at 2 ATA for four 30-min periods with intervening 10-min air breaks (a total oxygen dose of 2 h). Inclusion spanned 1985-1989. RESULTS: There were 10 patients who were treated 11 times for Type I altitude decompression sickness. Treatment was successful in 91%. There was one failure (a recurrence of elbow pain) requiring further therapy. Two patients were treated for Type II altitude decompression sickness. Treatment was successful in 50%. There was one failure (incomplete clearance of sensory deficits and weakness in the shoulder) requiring further therapy. CONCLUSION: Although TT8 had two failures, its successes suggest that a new protocol for the treatment of altitude decompression sickness is viable. In addition, its successes further suggest that a more extensive clinical trial is in order.
机译:简介:自1941年以来,就已经通过高压疗法治疗了高原减压病(DCS)。治疗基本上遵循了潜水DCS范式。不断扩大的太空作战和更高的飞行速度,更偏远的军用飞机刺激了人们对该范式的重新审视。是否可以在不牺牲治疗功效的情况下减少这些严酷环境中的氧气和压力产生资源?方法:采用新治疗表对12例患者进行前瞻性治疗。美国空军的治疗表8(TT8)由100%的氧气在2个ATA处输送,持续四个30分钟,其中有10分钟的空气中断(总氧气剂量为2小时)。纳入时间跨度1985-1989年。结果:有10例患者因I型高原减压病接受了11次治疗。 91%的患者治疗成功。有一种失败(肘部疼痛复发)需要进一步治疗。两名患者接受了II型高原减压病的治疗。治疗成功率为50%。有一种失败(感觉缺陷清除不彻底和肩膀无力)需要进一步治疗。结论:尽管TT8有两次失败,但它的成功表明,一种新的治疗高原减压病的方案是可行的。此外,它的成功进一步表明有必要进行更广泛的临床试验。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号